P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL

• P. Ghia,
• G. Barnes,
• K. Yang,
• C. Tam,
• P. Hillmen,
• T. Robak,
• J. Brown,
• B. Kahl,
• T. Tian,
• A. Szeto,
• J. Paik,
• M. Shadman

Affiliations

P. Ghia

1 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

G. Barnes

2 BeiGene USA, Inc., San Mateo, United States of America

K. Yang

2 BeiGene USA, Inc., San Mateo, United States of America

C. Tam

3 Peter MacCallum Cancer Centre, Melbourne

P. Hillmen

7 St James’s University Hospital, Leeds, United Kingdom

T. Robak

8 Medical University of Lodz, Lodz, Poland

J. Brown

9 Dana-Farber Cancer Institute, Boston

B. Kahl

10 Washington University School of Medicine, St. Louis

T. Tian

2 BeiGene USA, Inc., San Mateo, United States of America

A. Szeto

2 BeiGene USA, Inc., San Mateo, United States of America

J. Paik

2 BeiGene USA, Inc., San Mateo, United States of America

M. Shadman

11 Fred Hutchinson Cancer Research Center